Chemotherapy schedules
Induction chemotherapy | |
H-DAT schedule | |
Course 1 (DAT 3+10) | Daunorubicin 50 mg/m2 daily IV, d 1, 3, and 5 |
Cytosine arabinoside 200 mg/m2 twice a day, d 1-10 | |
Thioguanine 100 mg/m2 twice a day, d 1-10 | |
Course 2 (DAT 3+8) | Daunorubicin 50 mg/m2 daily IV, d 1, 3, and 5 |
Cytosine arabinoside 200 mg/m2 twice a day, d 1-8 | |
Thioguanine 100 mg/m2 twice a day, d 1-8 | |
FLAG-Ida schedule | |
Courses 1 and 2 | Fludarabine 30 mg/m2 IV, d 2-6 |
Cytosine arabinoside 2 g/m2 d 2-6 | |
G-CSF 263 μg SC, d 1-7 | |
Idarubicin 10 mg/m2 IV, d 4-6 | |
Consolidation chemotherapy | |
Course 3 (MACE) | Amsacrine 100 mg/m2 IV, d 1-5 |
Cytosine arabinoside 200 mg/m2 Cl, d 1-5 | |
Etoposide 100 mg/m2 IV, d 1-5 | |
Course 4 (MidAC) | Mitoxantrone 10 mg/m2 d 1-5 |
Cytosine arabinoside 1 g/m2 twice a day, d 1-3 | |
Courses 3 and 4 (HidAC) | Cytosine arabinoside 3 g/m2 twice a day, d 1, 3, and 5 |
Induction chemotherapy | |
H-DAT schedule | |
Course 1 (DAT 3+10) | Daunorubicin 50 mg/m2 daily IV, d 1, 3, and 5 |
Cytosine arabinoside 200 mg/m2 twice a day, d 1-10 | |
Thioguanine 100 mg/m2 twice a day, d 1-10 | |
Course 2 (DAT 3+8) | Daunorubicin 50 mg/m2 daily IV, d 1, 3, and 5 |
Cytosine arabinoside 200 mg/m2 twice a day, d 1-8 | |
Thioguanine 100 mg/m2 twice a day, d 1-8 | |
FLAG-Ida schedule | |
Courses 1 and 2 | Fludarabine 30 mg/m2 IV, d 2-6 |
Cytosine arabinoside 2 g/m2 d 2-6 | |
G-CSF 263 μg SC, d 1-7 | |
Idarubicin 10 mg/m2 IV, d 4-6 | |
Consolidation chemotherapy | |
Course 3 (MACE) | Amsacrine 100 mg/m2 IV, d 1-5 |
Cytosine arabinoside 200 mg/m2 Cl, d 1-5 | |
Etoposide 100 mg/m2 IV, d 1-5 | |
Course 4 (MidAC) | Mitoxantrone 10 mg/m2 d 1-5 |
Cytosine arabinoside 1 g/m2 twice a day, d 1-3 | |
Courses 3 and 4 (HidAC) | Cytosine arabinoside 3 g/m2 twice a day, d 1, 3, and 5 |
S-DAT was identical to H-DAT except the cytosine arabinoside dose was 100 mg/m2 twice a day; DA was identical to S-DAT with the exclusion of thioguanine.
IV indicates intravenously; G-CSF, granulocyte colony-stimulating factor; SC, subcutaneously, and CI, continuous infusion.